Media reports about Phase I/II data on MDV3100

There have been numerous media reports about on-line publication of data from a Phase I/II clinical trial of MDV3100 over the past 2 days. Here is a link to just one example.

These data were actually presented by Scher et al. at the annual meeting of the American Society of Clincial Oncology (ASCO) nearly a year ago, and we referenced these data at that time.

Here is a link to the actual on-line publication in The Lancet, which basically provided information defining the appropriate dose for MDV3100 in the now-ongoing Phase III clinical trial in patients with castrate-resistant prostate cancer (CRPC) who have already progressed after treatment with Taxotere-based chemotherapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: